Why are patients with malignant lymphomas excluded from clinical trials? The experience of an Oncology Institute in Italy [1]

European Journal of Cancer

Volumn 34, Issue 3, 1998, Pages 427-428

  Serraino, D ^a   Zagonel, V ^a   Bordonaro, R ^a   Franceschi, S ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; AGED; CANCER GRADING; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HODGKIN DISEASE; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PATIENT SELECTION; PRIORITY JOURNAL;

EID: 17344390590     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)00375-4     Document Type: Article

References (5)

1. 1. Kenney BJ. Needed clinical trials for older patients. J Clin Oncol 1991, 9, 718-720.
2. 2. Culliton BJ. Easier access to clinical trials. Nature Med 1997, 4, 369.
3. 3. Hancock BW, Aitken M, Radstone C, Vaughan Hudson G. Why don't cancer patients get entered into clinical trials? Experience of the Sheffield Lymphoma Group's collaboration in British National Lymphoma Investigation studies. BMJ 1997, 314, 36-37.
4. 4. Fentiman I, Trelli U, Monfardini S, et al. Cancer in the elderly: why so badly treated? Lancet 1990, 28, 1020-1022.
5. 5. Astrow AB. Rethinking cancer. Lancet 1994, 343, 494-495.